Related Experiment Video
Updated: Jun 12, 2025
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
6.8K
Transformable peptide blocks NF-κB/IκBα pathway through targeted coating IκBα against rheumatoid arthritis
Linhong Liu1, Mengru Ding2, Miaomiao Zheng3
1CAS Key Laboratory for the Biological Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, 100049, PR China; College of Chemistry and Life Science, Beijing University of Technology, Beijing, 100124, PR China.
Biomaterials
|September 17, 2024
Summary
A novel peptide transforms into nanoparticles to treat rheumatoid arthritis (RA). This peptide blocks key inflammatory pathways, reducing joint swelling and tissue destruction in a rat model, offering a new therapeutic strategy for autoimmune diseases.
Area of Science:
- Biomedical Engineering
- Immunology
- Nanotechnology
Background:
- Rheumatoid arthritis (RA) is a complex autoimmune disease with destructive effects.
- Current therapies targeting single inflammatory cytokines are often insufficient due to RA's multifaceted pathogenesis.
- There is a need for novel therapeutic strategies to effectively manage RA progression.
Purpose of the Study:
- To develop and evaluate an intelligent, transformable peptide (BFD) for treating rheumatoid arthritis.
- To investigate BFD's self-assembly, cellular uptake, and mechanism of action in immune cells.
- To assess BFD's therapeutic efficacy in an established collagen-induced arthritis (CIA) rat model.
Main Methods:
- Development of a transformable peptide (BP-FFVLK-DSGLDSM, BFD) capable of self-assembly into nanoparticles.
- Investigation of BFD's interaction with IκBα phosphorylation sites within immune cells.
- Assessment of BFD's ability to inhibit NF-κB signaling and reduce proinflammatory mediators.
- Evaluation of BFD's efficacy in a collagen-induced arthritis (CIA) rat model, measuring joint swelling, tissue damage, and bone/cartilage destruction.
Main Results:
- BFD self-assembles into nanoparticles for enhanced delivery and distribution.
- BFD effectively targets and transforms within immune cells, blocking IκBα phosphorylation and NF-κB activation.
- BFD significantly alleviates arthritis manifestations, including joint swelling and bone/cartilage destruction in the CIA rat model.
- Therapeutic outcomes correlate with BFD's biodistribution, IκBα inhibition, and reduction in inflammatory cytokines.
Conclusions:
- The transformable peptide BFD demonstrates significant therapeutic potential for rheumatoid arthritis.
- BFD's unique mechanism of action offers a novel approach to managing inflammatory diseases by targeting key intracellular signaling pathways.
- This study highlights the promise of intelligent peptide-based nanomaterials in autoimmune disease therapy.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
7.3K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
01:16TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
01:24T Cell Types and Functions
960
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
960
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145